Asia Pacific Anticoagulant Reversal Drugs Market By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), By Product Type (Idarucizumab, Andexanet Alfa, Prothrombin Complex Concentrates, Phytonadione, Protamine and Others), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Asia Pacific Anticoagulant Reversal Drugs Market
Market Report Description
The Asia Pacific Anticoagulant Reversal Drugs Market would witness market growth of 14.6% CAGR during the forecast period (2021-2027). Anticoagulant reversal drugs aim to reverse the effect of anticoagulation in some specific situations like unplanned surgery, therapy including overdose of anticoagulant, and excessive bleeding. Anticoagulant reversal drugs are useful in the treatment of different medical conditions like venous thromboembolism, mechanical valve replacement, and atrial fibrillation (AF). It is also used in coagulation disorders like Factor V Leiden and antiphospholipid antibody syndrome. The factor like the increasing prevalence of atrial fibrillation (AFib) and cardiac stroke is acting as a catalyst for global market. Though, growth of the market would be hampered by the the huge cost of anticoagulant reversal drugs.
The major contributing factors to the market growth include the increasing prevalence of multiple cardiovascular indications and atrial fibrillation across the world. The increase in intracranial and gastrointestinal hemorrhages and the increasing geriatric population around the world are also propelling the demand for anticoagulant reversal drugs. According to the World Health Organization, more than 17.9 million people die due to different kinds of cardiovascular diseases each year around the globe. It is about 35% of global deaths. Moreover, 85% of these cardiovascular disease deaths are caused by heart attack and stroke. The increasing approval of blockbuster drug and the presence of a strong pipeline of products among key players will also play a pivotal role in helping the market to expand further.
In the Asia Pacific, there is an increasing number of cases for bleeding disorders among people. The introduction of new drugs and therapeutics and the cases requiring anticoagulant therapies in this region are major factors anticipated to boost the market growth during the forecast period. Atrial fibrillation (AF) is a type of commonly sustained arrhythmia that increased mortality and stroke rate among the people of Asia. As the Asian population is swiftly aging the expected population suffering from AF will reach nearly 72 million. The Asia Pacific will grow at the fastest rate in coming years with the increment in the number of patients suffering from diseases like strokes, atrial fibrillation, and other cardiopulmonary diseases. Ongoing trials of anticoagulant drugs in this region will further drive regional market growth.
The Idarucizumab market dominated the Singapore Anticoagulant Reversal Drugs Market by Product Type in 2020, thereby, achieving a market value of $8.5 million by 2027. The Andexanet Alfa market is estimated to grow at a CAGR of 14.7% during (2021-2027). Additionally, The Prothrombin Complex Concentrates market is expected to witness highest CAGR of 16.1% during (2021-2027).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product Type, the market is segmented into Idarucizumab, Andexanet Alfa, Prothrombin Complex Concentrates, Phytonadione, Protamine and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Anticoagulant Reversal Drugs Market is Projected to reach USD 1.6 Billion by 2027, at a CAGR of 13.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, CSL Limited, Bausch Health Companies, Inc., Octapharma AG, Pfizer, Inc., Fresenius SE & Co. KGaA, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), Dr. Reddy’s Laboratories Ltd., AMAG Pharmaceuticals, Inc. (Covis Pharma), and Alps Pharmaceutical Ind. Co., Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Product Type
- Idarucizumab
- Andexanet Alfa
- Prothrombin Complex Concentrates
- Phytonadione
- Protamine
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Boehringer Ingelheim International GmbH
- CSL Limited
- Bausch Health Companies, Inc.
- Octapharma AG
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
- Dr. Reddy’s Laboratories Ltd.
- AMAG Pharmaceuticals, Inc. (Covis Pharma)
- Alps Pharmaceutical Ind. Co., Ltd.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free